Scholarlink

Purpose <p>This study aims to characterize SMARCA4-deficient tumors using <sup>18</sup>F-FDG PET/CT and explore its role in diagnosis, staging, therapeutic response assessment, and prognosis across multiple pathological subtypes.</p> Methods <p>We retrospectively analyzed four patients with histologically confirmed SMARCA4-deficient tumors. Clinical features,<sup>18</sup>F-FDG PET/CT findings, pathological subtypes, molecular characteristics, treatment modalities, and outcomes were evaluated.</p> Results <p>All tumors demonstrated high FDG uptake, indicating elevated metabolic activity. Imaging patterns varied by subtype, including undifferentiated carcinoma and non-small cell lung cancer. Treatment strategies involved chemotherapy, immunotherapy, and targeted therapy with diverse responses. SMARCA4 deficiency was associated with poor prognosis and potential treatment resistance.</p> Conclusion <p><sup>18</sup>F-FDG PET/CT is valuable in the comprehensive assessment of SMARCA4-deficient tumors. Combined with molecular profiling, it enhances diagnostic accuracy and aids in individualized treatment planning. This case series offers preliminary guidance for clinicians managing this rare, aggressive tumor type.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月3日

查看全文
  • Xueqin Zhao,
  • Wei Fu

摘要

Purpose

This study aims to characterize SMARCA4-deficient tumors using 18F-FDG PET/CT and explore its role in diagnosis, staging, therapeutic response assessment, and prognosis across multiple pathological subtypes.

Methods

We retrospectively analyzed four patients with histologically confirmed SMARCA4-deficient tumors. Clinical features,18F-FDG PET/CT findings, pathological subtypes, molecular characteristics, treatment modalities, and outcomes were evaluated.

Results

All tumors demonstrated high FDG uptake, indicating elevated metabolic activity. Imaging patterns varied by subtype, including undifferentiated carcinoma and non-small cell lung cancer. Treatment strategies involved chemotherapy, immunotherapy, and targeted therapy with diverse responses. SMARCA4 deficiency was associated with poor prognosis and potential treatment resistance.

Conclusion

18F-FDG PET/CT is valuable in the comprehensive assessment of SMARCA4-deficient tumors. Combined with molecular profiling, it enhances diagnostic accuracy and aids in individualized treatment planning. This case series offers preliminary guidance for clinicians managing this rare, aggressive tumor type.